autologous iNSC-DAP
/ Huixin Medical Valley
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
July 02, 2026
Safety and Efficacy of Autologous iNSC-DAP in the Treatment of Parkinson's Disease
(clinicaltrials.gov)
- P1 | N=6 | Recruiting | Sponsor: Xuanwu Hospital, Beijing | N=10 ➔ 6 | Trial completion date: Dec 2026 ➔ Dec 2028 | Trial primary completion date: Dec 2025 ➔ Dec 2027
Enrollment change • Trial completion date • Trial primary completion date • CNS Disorders • Movement Disorders • Parkinson's Disease
June 13, 2023
Safety and Efficacy of Autologous iNSC-DAP in the Treatment of Parkinson's Disease
(clinicaltrials.gov)
- P1 | N=10 | Recruiting | Sponsor: Xuanwu Hospital, Beijing
New P1 trial • CNS Disorders • Movement Disorders • Parkinson's Disease
1 to 2
Of
2
Go to page
1